She started looking at old psychological studies exploring human nature and became fascinated by the Stanford Prison ...

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...

The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...

The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, multi-part single and multiple ascending dose clinical study is to evaluate the safety, tolerability and ...

Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

The Study 304 (NCT04959032) trial met its primary endpoint of time to relapse during the 26-week double-blind treatment phase, with Caplyta treatment associated with a 63% reduction in the risk of ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

double-blind, placebo-controlled trial. The findings align with an earlier study that showed possible disease-modifying ...

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...